Neurodegeneration and inflammation in MS
The eye teaches us about the storm
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In multiple sclerosis (MS), neurodegeneration contributes to axon loss and irreversible disability, but the degree to which neurodegeneration is a consequence of inflammatory mechanisms is unknown. Urgent need exists in all forms of MS, but especially in progressive MS, for therapies that preserve the integrity and function of CNS tissue in the face of a partially controlled chronic disease. It is likely that agents envisioned to fulfill that role (primary neuroprotective therapies) will act via a mechanism outside immune modulation. In analogous terms, the CNS could be likened to a home that we aim to protect from storm damage. Immune-modulating therapies are the equivalent of a weather machine that prevents the storm from ever brewing, and in that way provide indirect neuroprotection. Primary neuroprotection would be achieved by another mechanism, something akin to installing storm shutters or reinforcing the structure of a home to help it weather the years. The concern in MS is that ongoing neurodegeneration may occur even in the absence of detectable active inflammation, compelling a need for primary neuroprotective therapies that utilize novel mechanisms of action.
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 47
- © 2012 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.